Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
An independent committee investigating Ono Pharmaceutical’s bribery scandal has compiled a report calling on the company to set up a foundation to review and disburse “scholarship donations” in order to eliminate any involvement of commercial divisions in the granting of…
To read the full story
Related Article
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
BUSINESS
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Sanwa Files Paltusotine in Japan for Acromegaly, Pituitary Gigantism
April 16, 2026
- Shionogi’s CVC Makes First Investment in Restore Vision
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…